Table 3 AUC (adjusted) values for differentiation of CD vs. non-IBD, UC vs. non-IBD, and CD vs. UC using a GB classifier with 5-fold cross-validation under MAR, MCAR, and MNAR mechanisms.

From: Imputation methods for serologic biomarkers in inflammatory bowel disease

Percentage

MAR

MCAR

MNAR

CD vs. non-IBD

 5

II (BR)

0.859

II (BR)

0.861

II (BR)

0.855

 10

II (BR)

0.849

II (BR)

0.854

II (BR)

0.843

 15

II (BR)

0.841

II (BR)

0.848

II (BR)

0.832

 20

II (BR)

0.834

II (BR)

0.840

II (BR)

0.825

 25

II (BR)

0.827

II (BR)

0.833

II (BR)

0.817

 30

II (BR)

0.821

II (BR)

0.825

II (BR)

0.814

 35

II (BR)

0.813

AE

0.815

AE

0.806

 40

II (BR)

0.804

AE

0.806

AE

0.804

 Original data

0.866

UC vs. non-IBD

 5

AE

0.805

AE

0.804

II (RF)

0.804

 10

AE

0.795

AE

0.795

II (RF)

0.782

 15

AE

0.785

AE

0.785

II (RF)

0.770

 20

AE

0.775

AE

0.775

II (RF)

0.759

 25

AE

0.741

AE

0.763

AE

0.749

 30

AE

0.719

AE

0.751

AE

0.738

 35

AE

0.699

AE

0.738

AE

0.731

 40

II (BR)

0.684

AE

0.724

AE

0.721

 Original data

0.816

CD vs. UC

 5

II (BR)

0.821

II (BR)

0.821

II (RF)

0.821

 10

II (BR)

0.819

II (BR)

0.818

II (BR)

0.813

 15

II (BR)

0.816

II (BR)

0.815

II (BR)

0.807

 20

II (BR)

0.814

II (BR)

0.811

II (BR)

0.803

 25

II (BR)

0.812

II (BR)

0.806

II (BR)

0.798

 30

II (BR)

0.809

II (BR)

0.800

II (BR)

0.793

 35

II (BR)

0.806

AE

0.793

II (BR)

0.788

 40

II (BR)

0.801

AE

0.787

AE

0.784

 Original data

0.823

  1. Iterative imputers (especially II(BR)) consistently maintain the highest classification performance in CD-related tasks, while AE becomes competitive at higher missingness levels. In UC vs. non-IBD, AE generally outperforms other methods across most missingness degrees, whereas II(RF) shows an advantage in MNAR at low missingness.